GI
CRL icon

GAMMA Investing’s Charles River Laboratories CRL Stock Holding History

GAMMA Investing’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.3M Buy
4,406
+630
+17% +$166K 0.04% 345
2026
Q2 		$856K Buy
3,776
+308
+9% +$54.8K 0.03% 446
2026
Q1 		$598K Sell
3,468
-186
-5% -$34.5K 0.03% 507
2025
Q4 		$729K Buy
3,654
+1,213
+50% +$220K 0.04% 406
2025
Q3 		$382K Buy
2,441
+569
+30% +$90.4K 0.02% 605
2025
Q2 		$284K Buy
1,872
+474
+34% +$63.2K 0.02% 696
2025
Q1 		$210K Buy
1,398
+533
+62% +$89.4K 0.02% 738
2024
Q4 		$160K Sell
865
-176
-17% -$33.9K 0.01% 805
2024
Q3 		$205K Buy
1,041
+192
+23% +$39.9K 0.02% 613
2024
Q2 		$175K Buy
849
+412
+94% +$93.4K 0.02% 542
2024
Q1 		$118K Buy
437
+151
+53% +$36.1K 0.02% 582
2023
Q4 		$61.9K Buy
+286
New +$56.2K 0.02% 777

Other funds holding CRL

CIM
Confluence Investment Management St. Louis, Missouri $5.97B AUM 5.11% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
LHWM
Lake Hills Wealth Management Austin, Texas $218M AUM 31.66% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
MGI
Miller Global Investments Dallas, Texas $124M AUM 25.7% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
EWP
Elevation Wealth Partners Santa Rosa, California $356M AUM 17.04% 1-Year Est. Return

GAMMA Investing's CRL Position: Q3 2026 in Review

GAMMA Investing increased its Charles River Laboratories (CRL) stake by 17% in Q3 2026, buying an estimated $166K and bringing the position to 4,406 shares worth $1.3M. The position accounts for 0.04% of the portfolio, ranked #345.

GAMMA Investing first reported a position in CRL in Q4 2023 and has held it in 12 quarters since. 15 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • GAMMA Investing held 4,406 shares of Charles River Laboratories worth $1.3M as of Q3 2026.
  • GAMMA Investing bought 630 Charles River Laboratories shares in Q3 2026, an estimated $166K.
  • Charles River Laboratories made up 0.04% of GAMMA Investing's portfolio in Q3 2026, its #345 holding.
  • GAMMA Investing first reported a position in Charles River Laboratories in Q4 2023 and has held it in 12 quarters since.
  • 15 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.